Literature DB >> 16044098

Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients.

Yolanda Armendáriz1, Leonor Pou, Carme Cantarell, Rosa Lopez, Manuel Perelló, Lluis Capdevila.   

Abstract

Limited sampling strategies have been developed to predict full AUCs. The goal of this study was to develop a limited sampling strategy to estimate the AUC of tacrolimus in adult renal transplant patients and to evaluate its predictive performance in an independent patient population. A total of 27 tacrolimus pharmacokinetic profiles were studied. Blood samples were collected before the dose (0) and at 0.5, 1, 2, 4, 6, 8, and 12 hours postdose. The study was divided into 2 phases. In phase 1, the goal was to obtain a sampling strategy from 14 pharmacokinetic profiles. In phase 2, the bias and precision of the model were evaluated in another 13 pharmacokinetic profiles. The best correlation was achieved at 4 hours after dose (r(2) = 0.790). Stepwise multiple regression analysis determined that the abbreviated AUC at 0, 1, and 4 hours could accurately predict total AUC (r(2) = 0.965). The following formula was developed: AUC = 8.90 + 4.0C0h+ 1.77C1h + 5.47C4h. No significant differences were found between calculated and estimated AUC (165.6 +/- 41.1 and 166.7 +/- 43.2 ng.h/mL, respectively). The mean prediction error (MPE), the relative prediction error (PE), and the mean squared error (MSE) were 0.48 ng.h/mL, 0.16%, and 40.0 ng.h/mL, respectively. The limited sampling with use of the 3 levels at 0, 1, and 4 hours postdose provides accurate, reliable determination of tacrolimus AUC in renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044098     DOI: 10.1097/01.ftd.0000158080.61201.65

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  A limited sampling strategy for tacrolimus in renal transplant patients.

Authors:  Binu S Mathew; Denise H Fleming; Visalakshi Jeyaseelan; Sujith J Chandy; V M Annapandian; P K Subbanna; George T John
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

3.  Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.

Authors:  Tania Claeys; Maria Van Dyck; Rita Van Damme-Lombaerts
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

4.  Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.

Authors:  David Czock; Frieder Keller; Hanna M Seidling
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 5.  Once- versus twice-daily tacrolimus: are the formulations truly equivalent?

Authors:  Katherine A Barraclough; Nicole M Isbel; David W Johnson; Scott B Campbell; Christine E Staatz
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

6.  Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation.

Authors:  Itziar Oteo; John C Lukas; Nerea Leal; Elena Suarez; Andres Valdivieso; Mikel Gastaca; Jorge Ortiz de Urbina; Rosario Calvo
Journal:  Eur J Clin Pharmacol       Date:  2011-02-17       Impact factor: 2.953

7.  Evaluation of limited sampling strategies for tacrolimus.

Authors:  Robert A M Op den Buijsch; Afke van de Plas; Leo M L Stolk; Maarten H L Christiaans; Johannes P van Hooff; Nas A Undre; Marja P van Dieijen-Visser; Otto Bekers
Journal:  Eur J Clin Pharmacol       Date:  2007-08-22       Impact factor: 2.953

8.  The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Authors:  Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

9.  Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.

Authors:  Yuen Yi Hon; Christine E Chamberlain; David E Kleiner; Michael S Ring; Douglas A Hale; Allan D Kirk; Roslyn B Mannon
Journal:  Clin Transplant       Date:  2010 Jul-Aug       Impact factor: 2.863

Review 10.  Clinical aspects of tacrolimus use in paediatric renal transplant recipients.

Authors:  Agnieszka Prytuła; Teun van Gelder
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.